This announcement is a separate document:
復旦張江：提示性公告-注射用 FDA018 抗體偶聯劑用於治療三陰性乳腺癌III期臨床試驗完成首例受試者入組
FUDANZHANGJIANG: INDICATIVE ANNOUNCEMENT-FIRST PATIENT ENROLLED IN PHASE III CLINICAL TRIAL OF FDA018 ANTIBODY DRUG CONJUGATE FOR INJECTION FOR THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated